These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

912 related articles for article (PubMed ID: 21709061)

  • 1. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?
    Waxman AB
    Circulation; 2011 Jul; 124(2):133-5. PubMed ID: 21747065
    [No Abstract]   [Full Text] [Related]  

  • 3. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
    Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
    Andersen MJ; Hwang SJ; Kane GC; Melenovsky V; Olson TP; Fetterly K; Borlaug BA
    Circ Heart Fail; 2015 May; 8(3):542-50. PubMed ID: 25857307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter by Jamous regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
    Jamous FG
    Circulation; 2012 Feb; 125(8):e407; author reply e409-10. PubMed ID: 22371449
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
    Forfia PR; Borlaug BA
    Circulation; 2012 Feb; 125(8):e408; author reply e409-10. PubMed ID: 22371450
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter by Gordon et al regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
    Gordon B; McDiarmid A; MacGowan G
    Circulation; 2012 Feb; 125(8):e406; author reply e409-10. PubMed ID: 22371448
    [No Abstract]   [Full Text] [Related]  

  • 11. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.
    Guazzi M; Dixon D; Labate V; Beussink-Nelson L; Bandera F; Cuttica MJ; Shah SJ
    JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1211-1221. PubMed ID: 28412423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R
    Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine.
    Karakitsos D; Papanikolaou J; Karabinis A; Alalawi R; Wachtel M; Jumper C; Alexopoulos D; Davlouros P
    Int J Cardiol; 2013 Aug; 167(3):848-54. PubMed ID: 22386699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial.
    Andersen MJ; Ersbøll M; Axelsson A; Gustafsson F; Hassager C; Køber L; Borlaug BA; Boesgaard S; Skovgaard LT; Møller JE
    Circulation; 2013 Mar; 127(11):1200-8. PubMed ID: 23406672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone.
    Lewis GD; Shah RV; Pappagianopolas PP; Systrom DM; Semigran MJ
    Circ Heart Fail; 2008 Nov; 1(4):227-33. PubMed ID: 19808296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.